Page last updated: 2024-11-07

3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID119553
CHEMBL ID52948
SCHEMBL ID3513494
MeSH IDM0140881

Synonyms (17)

Synonym
87627-28-9
bdbm50038587
8-(3-methyl-2-pyridin-3-yl-indol-1-yl)-octanoic acid
cgs-12970
1h-indole-1-octanoic acid, 3-methyl-2-(3-pyridinyl)-
3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid
cgs 12970
3-methyl-2-(3-pyridinyl)-1h-indole-1-octanoic acid
CHEMBL52948 ,
unii-gdv947f7uo
gdv947f7uo ,
1h-indole-1-octanoic acid,3-methyl-2-(3-pyridinyl)-
SCHEMBL3513494
CVVKIXNPXDBREE-UHFFFAOYSA-N
1-(7-carboxyheptyl)-3-methyl-2-(3-pyridyl)indole
DTXSID30236537
PD159627

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"The pharmacokinetics and pharmacodynamics of biochemical effect of a selective thromboxane synthase inhibitor, CGS 12970, were studied in healthy male volunteers after a dosing scheme of either 200 mg once daily or 100 mg twice a day for 6 days."( Pharmacokinetics of CGS 12970 and inhibition of thromboxane synthesis after oral administration in healthy adults.
Douglas, FL; Linberg, L; Martin, LL; Piraino, A; Rakhit, A; Schaffer, AV; Singh, K, 1991
)
0.28
"A specific thromboxane synthetase inhibitor, 3-methyl-2 (3-pyridyl)-1-indoleoctanoic acid (CGS 12970) was administered orally to 6 healthy adult Beagles at a dosage of 30 mg/kg of body weight."( Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs.
Culham, CA; Grauer, GF; Johnson, HC; Longhofer, SL; Schultz, KT, 1990
)
0.28
" In-vitro dose-response experiments revealed that CGS-12970 nonselectively inhibited renal allograft tissue TXB2 and 6-K-PGF1 alpha production in a dose-dependent manner."( Effects of the thromboxane synthesis inhibitor CGS-12970 on experimental acute renal allograft rejection.
Anderson, CB; Brunt, EM; Mangino, MJ; Von Doersten, P, 1989
)
0.28
" However, twice daily dosing with dazoxiben was effective."( Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
Ambler, J; Butler, KD; Butler, PA; Shand, RA; Wallis, RB, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)0.01200.00091.230410.0000AID212096
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID37782Tested for 50% inhibition of Angiotensin converting enzyme(ACE) obtained from rabbit lung (in vitro); Not active1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
AID212096Tested for 50% inhibition of thromboxane synthase (TxS) in human platelets (in vitro)1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (34.29)18.7374
1990's21 (60.00)18.2507
2000's1 (2.86)29.6817
2010's1 (2.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.84 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.78%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.78%)4.05%
Observational0 (0.00%)0.25%
Other34 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]